Notice for burosumab (Kyowa Kirin Australia Pty Ltd)
Active ingredients
burosumab
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
for the treatment of X-linked hypophosphataemia in adult and paediatric patients 1 year of age or older
Therapeutic area
Endocrinology